Hikma Pharmaceuticals (HIK) Stock Overview
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
HIK Community Fair Values
Create NarrativeSee what 59 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.675.0% undervalued intrinsic discount
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeHikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£14.08 |
| 52 Week High | UK£21.64 |
| 52 Week Low | UK£11.87 |
| Beta | 0.61 |
| 1 Month Change | 7.65% |
| 3 Month Change | -13.73% |
| 1 Year Change | -29.95% |
| 3 Year Change | -24.26% |
| 5 Year Change | -38.81% |
| Change since IPO | 399.29% |
Recent News & Updates
HIK: Buyback Plan And Index Shift Will Support Future Re Rating
Analysts have trimmed their fair value estimate for Hikma Pharmaceuticals to about £18.84 from £19.17, reflecting reduced price targets to £18.00 and £20.00 as they factor in slightly lower assumed revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts continue to see upside, keeping positive ratings in place even as price targets are trimmed to £18.00 and £20.00, which still sit above the revised fair value estimate of about £18.84.HIK: Index Move And Buyback Plan Will Support Future Re Rating
Narrative Update: Hikma Pharmaceuticals The analyst price target for Hikma Pharmaceuticals has been reset towards a lower Street range, with recent cuts to £18.00 and £20.00. These figures inform a modestly higher fair value estimate of £19.17, supported by analysts referencing updated assumptions on revenue growth, profit margins and future P/E levels.Recent updates
HIK: Buyback Plan And Index Shift Will Support Future Re Rating
Analysts have trimmed their fair value estimate for Hikma Pharmaceuticals to about £18.84 from £19.17, reflecting reduced price targets to £18.00 and £20.00 as they factor in slightly lower assumed revenue growth, profit margin and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts continue to see upside, keeping positive ratings in place even as price targets are trimmed to £18.00 and £20.00, which still sit above the revised fair value estimate of about £18.84.HIK: Index Move And Buyback Plan Will Support Future Re Rating
Narrative Update: Hikma Pharmaceuticals The analyst price target for Hikma Pharmaceuticals has been reset towards a lower Street range, with recent cuts to £18.00 and £20.00. These figures inform a modestly higher fair value estimate of £19.17, supported by analysts referencing updated assumptions on revenue growth, profit margins and future P/E levels.HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating
Hikma Pharmaceuticals' updated fair value estimate has edged down slightly to £19.02 per share from £19.06. This reflects a series of reduced analyst price targets between £1,600 and £2,000, along with their increased focus on management uncertainty, strategic direction, and a more conservative P/E outlook.HIK: Buyback Plan And Leadership Changes Will Support Future Re Rating
The analyst price target for Hikma Pharmaceuticals has been reduced by £1.41 per share. This change reflects updated fair value assumptions and ongoing analyst concerns around management visibility, strategic direction, and the near-term earnings outlook.
Injectable Expansion And MENA Scale Will Shape A Cautious Yet Steady Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops and supplies generic and branded medicines, including injectables, across MENA and the US. What are the underlying business or industry changes driving this perspective?HIK: Leadership Change And Buyback Plan Will Support Future Re Rating Potential
Analysts have trimmed their price expectations for Hikma Pharmaceuticals, with our updated fair value moving from £21.82 to £20.47. This reflects recent cuts to Street targets to £2,000 and £1,600, as well as increased caution around growth, margins and the P/E investors may be willing to pay.
Rising CMO And Injectable Pipelines Will Support A Stronger Long Term Outlook
Catalysts About Hikma Pharmaceuticals Hikma Pharmaceuticals develops, manufactures, and supplies branded, generic, and injectable medicines across MENA, Europe, and North America. What are the underlying business or industry changes driving this perspective?HIK: Leadership Change And Execution On Plans Will Support Re Rating Potential
Analysts have trimmed their fair value estimate for Hikma Pharmaceuticals from about £22.14 to £21.82, citing a slightly higher discount rate and lower future P/E assumptions following recent research that highlights uncertainty around management, strategy and potential catalysts. Analyst Commentary Recent research reflects a cautious tone on Hikma Pharmaceuticals, with the downgrade in rating and a £16.00 price target framed around execution risk and limited near term triggers for a re rating.HIK: Leadership Reset And New Guidance Will Support Earnings Outlook
Analysts have adjusted their price targets for Hikma Pharmaceuticals within a wide £1,600 to £2,400 range, reflecting differing views on management clarity, strategic direction, and available catalysts for the shares. Analyst Commentary Recent research on Hikma Pharmaceuticals shows a split between analysts who see upside potential and those who are more cautious, which helps explain the wide spread in price targets.HIK: Leadership Reset And 2030 Revenue Aim Will Underpin Earnings Outlook
Hikma Pharmaceuticals' updated fair value estimate has inched from £21.99 to £22.14 per share, reflecting mixed analyst views, as some raise price targets into the £23.00 range while others turn more cautious with Underweight ratings around £16.00 and cite uncertainty around management, strategy, and the outlook. Analyst Commentary Recent Street research on Hikma Pharmaceuticals highlights a clear split in opinion, with some analysts focusing on potential upside in execution and growth, while others flag risks around management direction and near term catalysts.HIK: Leadership Reset And 2030 Revenue Ambition Will Support Earnings Outlook
Analysts have reduced their fair value estimate for Hikma Pharmaceuticals from £22.66 to £22.00 per share, reflecting a combination of more cautious views on management, strategy and catalysts, together with recent recalibrations of price targets across covering banks. Analyst Commentary Recent Street research on Hikma Pharmaceuticals shows a split between more cautious and more optimistic voices, with differing price targets and ratings feeding into the reduced fair value estimate.HIK: US Approvals And Pipeline Expansion Will Drive Earnings Outlook Higher
Hikma Pharmaceuticals' analyst price target has been moderately revised as analysts balance a tighter fair value estimate of about $22.66 with slightly stronger expectations for revenue growth, margins, and supportive recent target changes in the 2,300 to 2,510 GBp range. Analyst Commentary Analyst commentary on Hikma Pharmaceuticals reflects a broadly constructive stance on the company, with recent target moves clustering within a relatively tight range and signaling confidence in the sustainability of its growth profile.Market Cool On Hikma Pharmaceuticals PLC's (LON:HIK) Earnings
Dec 01
HIK: Earnings Outlook Will Improve Following US Market Approval
Hikma Pharmaceuticals' analyst price target was revised modestly lower, from £23.55 to £23.36 per share. Analysts adjusted expectations reflecting a mix of target increases and decreases among recent Street research.HIK: Shares Will Benefit From U S Approval And Profitability Improvements
Analysts have slightly reduced their fair value estimate for Hikma Pharmaceuticals from £25.40 to £23.55. This reflects modest downward adjustments to near-term price targets along with updated assumptions for discount rates, growth, and margins.Expanded US Market Access Will Drive Momentum Amid Regulatory Headwinds
Hikma Pharmaceuticals' analyst price target was slightly raised to £25.40 from £25.02, as analysts cite updated growth and profitability forecasts. This comes despite recent downward adjustments in individual firm targets.Hikma Pharmaceuticals (LON:HIK) Has A Somewhat Strained Balance Sheet
Oct 27Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?
Sep 10US, Europe, And MENA Expansion Will Boost Global Pharmaceutical Demand
Hikma Pharmaceuticals’ Future P/E ratio has dropped sharply, indicating improved valuation relative to earnings expectations, while revenue growth forecasts remain steady, resulting in the consensus price target edging down slightly from £25.17 to £25.02. What's in the News Hikma maintained full-year 2025 group revenue growth guidance of 4–6%, with core operating profit expected at $730–770 million; injectable segment revenue growth is guided at 7–9%, branded revenue at 6–7%, and Rx revenue broadly flat versus 2024.Earnings Tell The Story For Hikma Pharmaceuticals PLC (LON:HIK)
Aug 02Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Jun 19Investors Appear Satisfied With Hikma Pharmaceuticals PLC's (LON:HIK) Prospects
Apr 08Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Mar 17
R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects
Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Shareholder Returns
| HIK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.8% | -3.5% | 0.4% |
| 1Y | -30.0% | 20.7% | 19.5% |
Return vs Industry: HIK underperformed the UK Pharmaceuticals industry which returned 20.7% over the past year.
Return vs Market: HIK underperformed the UK Market which returned 19.5% over the past year.
Price Volatility
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: HIK has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: HIK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,400 | Said Samih Darwazah | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| HIK fundamental statistics | |
|---|---|
| Market cap | UK£3.03b |
| Earnings (TTM) | UK£296.97m |
| Revenue (TTM) | UK£2.47b |
10.2x
P/E Ratio1.2x
P/S RatioIs HIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIK income statement (TTM) | |
|---|---|
| Revenue | US$3.35b |
| Cost of Revenue | US$1.89b |
| Gross Profit | US$1.46b |
| Other Expenses | US$1.06b |
| Earnings | US$402.00m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 43.51% |
| Net Profit Margin | 12.00% |
| Debt/Equity Ratio | 59.5% |
How did HIK perform over the long term?
See historical performance and comparisonDividends
4.4%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 09:56 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 26 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sidhartha Modi | Barclays |
| James Gordon | Barclays |
| Victoria Lambert | Berenberg |